Fig. 7. Coronal MIP fused SPECT and CT images at 3, 72, and 144 h post-injection of 18 MBq [¹¹¹In]In-DTPA-trastuzumab in the same mouse bearing an SK-OV-3 tumour (HER2-positive). Uptake of [¹¹¹In]In-DTPA-trastuzumab was observed in the tumour (T) and liver (L). The longer blood circulation of [¹¹¹In]In-DTPA-trastuzumab leads to an increased specific tumour uptake over time.